Somatostatin Acetate

醋酸生长抑素

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameSomatostatin Acetate
Drug Alias Namesomatostatina合成生长抑素生长抑素Somatostatin-14somatostatinum +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGrowth hormone releasing factor antagonists
TargetsGrowth hormone releasing factor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 1Pancreatitis +[6] 
Global Approved IndicationsPancreatitisGastrointestinal Hemorrhage
Approved Indications in ChinaPancreatitisGastrointestinal Hemorrhage
Original Approved Country/TerritoryCanada
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesEverest Medicines (China) Co LtdEverest Medicines LtdLyomark Pharma Gmbh +[4] 
Inactive CompaniesUniversity Of MinnesotaUcb PharmaMedical University Of Vienna
Active IndicationsObesityPancreatitisGastrointestinal Hemorrhage
Inactive IndicationsDiabetes Mellitus, Type 1Peptic UlcerCarcinoma, Hepatocellular

Other Information

ATC CodeH01CB01
Related LinksWikipediaDrugBankKEGG